Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution

Approximately 15% of breast cancers are classified as HER2-positive, with an amplification of the ERBB2 gene and/or an overexpression of the HER2 protein. Up to 30% of HER2-positive breast cancers shows heterogeneity in HER2 expression and different patterns of spatial distribution, i.e., the variability in the distribution and expression of the HER2 protein within a single tumour. Spatial heterogeneity may potentially affect treatment, response, assessment of HER2 status and consequently, may impact on the best treatment strategy. Understanding this feature can help clinicians to predict response to HER2-targeted therapies and patient outcomes, and to fine tune treatment decisions. This review summarizes the available evidence on HER2 heterogeneity and spatial distribution and how this may affect current available treatment choices, exploring possible opportunities for overcoming this issue, such as novel pharmacological agents, belonging to the group of antibody–drug conjugates.

[1]  Sung-Bae Kim,et al.  Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial , 2022, The Lancet.

[2]  S. Swain,et al.  Targeting HER2-positive breast cancer: advances and future directions , 2022, Nature Reviews Drug Discovery.

[3]  G. Bonizzi,et al.  Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer , 2022, Cells.

[4]  C. Criscitiello,et al.  Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls , 2022, Cancer drug resistance.

[5]  N. Fusco,et al.  Improving HER2 testing reproducibility in HER2-low breast cancer , 2022, Cancer drug resistance.

[6]  S. Tolaney,et al.  Overcoming Resistance to HER2-Directed Therapies in Breast Cancer , 2022, Cancers.

[7]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[8]  S. Loi,et al.  Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. , 2022, Journal of Clinical Oncology.

[9]  M. Lacroix-Triki,et al.  LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial , 2022, Annals of Oncology.

[10]  D. Lopez-Ramos,et al.  45P Spatially-resolved single-cell HER2 tumor heterogeneity captured by biophysical modeling , 2022, Annals of Oncology.

[11]  Min Hwan Kim,et al.  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.

[12]  G. Curigliano,et al.  Bystander effect of antibody–drug conjugates: fact or fiction? , 2022, Current Oncology Reports.

[13]  C. Criscitiello,et al.  HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer , 2022, Frontiers in Molecular Biosciences.

[14]  F. André,et al.  Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) , 2022, Cancer Research.

[15]  Amanda R. Kulick,et al.  HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway , 2021, Nature Communications.

[16]  Å. Borg,et al.  Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions , 2021, Nature Communications.

[17]  S. Loi,et al.  ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Cruz,et al.  Pharmacogenomic Application in HER2-positive Breast Cancer , 2021, International Journal of Clinical and Experimental Medicine Research.

[19]  R. Bose,et al.  Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance. , 2021, The New England journal of medicine.

[20]  J. O’Shaughnessy,et al.  LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer , 2021, Annals of Oncology.

[21]  E. Rutgers,et al.  Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  G. T. Budd,et al.  Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials. , 2021, Journal of Clinical Oncology.

[23]  E. Winer,et al.  Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. , 2021, Cancer discovery.

[24]  C. Geyer,et al.  Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Chandarlapaty,et al.  Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.

[26]  G. Ciliberto,et al.  Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study , 2020, Journal of experimental & clinical cancer research : CR.

[27]  G. Curigliano,et al.  Margetuximab for the treatment of HER2-positive metastatic breast cancer , 2020, Expert opinion on biological therapy.

[28]  Jennifer L. Caswell-Jin,et al.  Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response , 2020, Nature Cancer.

[29]  S. Tolaney,et al.  Targeting HER2 heterogeneity in early-stage breast cancer , 2020, Current opinion in oncology.

[30]  Sung-Bae Kim,et al.  Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Cardoso,et al.  HER2-Low Breast Cancer: Pathological and Clinical Landscape. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Polyak,et al.  Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. , 2020, Cancer cell.

[33]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.

[34]  A. Fernández-Santander,et al.  Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer , 2020, Journal of oncology.

[35]  A. Sapino,et al.  Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. , 2020, Seminars in cancer biology.

[36]  R. Gomis,et al.  Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade , 2020, Nature Communications.

[37]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[38]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[39]  B. Taylor,et al.  Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. , 2019, Cancer discovery.

[40]  D. Hayes.  HER2 and Breast Cancer - A Phenomenal Success Story. , 2019, The New England journal of medicine.

[41]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  G. Mariani,et al.  Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. , 2019, Critical reviews in oncology/hematology.

[43]  E. Perez,et al.  Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer , 2019, BMC Cancer.

[44]  P. Fasching,et al.  Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Sebra,et al.  Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  S. Piha-Paul,et al.  Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  F. Bertucci,et al.  Genomic characterization of metastatic breast cancers , 2019, Nature.

[48]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[49]  Johannes G. Reiter,et al.  Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy , 2019, Nature Communications.

[50]  F. Markowetz,et al.  Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors , 2018, bioRxiv.

[51]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[52]  G. Arpino,et al.  First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[54]  A. Parwani,et al.  HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma , 2017, Breast Cancer Research and Treatment.

[55]  S. Barni,et al.  Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature , 2017, Breast Cancer Research and Treatment.

[56]  Veeraraghavan,et al.  HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer , 2017, Clinical Cancer Research.

[57]  E. Perez,et al.  Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  R. Bernards,et al.  PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  I. Desideri,et al.  Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. , 2016, Cancer treatment reviews.

[60]  G. Hortobagyi,et al.  Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer , 2016, Oncotarget.

[61]  F. Cardoso,et al.  The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review , 2015, Breast Cancer Research.

[62]  John W. Adams,et al.  Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival , 2015, Breast Cancer Research.

[63]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[64]  An Na Seo,et al.  HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. , 2014, American journal of clinical pathology.

[65]  D. Rimm,et al.  A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. , 2014, Archives of pathology & laboratory medicine.

[66]  Xue-jun Fan,et al.  Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation , 2014, Breast Cancer Research.

[67]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  C. Sotiriou,et al.  Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer , 2013, Journal of the National Cancer Institute.

[69]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[70]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[71]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[72]  M. Tibiletti,et al.  Genetic heterogeneity in HER2 testing may influence therapy eligibility , 2012, Breast Cancer Research and Treatment.

[73]  I. Ellis,et al.  HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods , 2011, Journal of Clinical Pathology.

[74]  Hua Guo,et al.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.

[75]  Raymond R Tubbs,et al.  Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. , 2009, Archives of pathology & laboratory medicine.

[76]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[77]  T. Kute,et al.  Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing , 2009, Cancer Immunology, Immunotherapy.

[78]  J. Isola,et al.  Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. , 2007, European journal of cancer.

[79]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[80]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[81]  J. Baselga,et al.  Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. , 2007, Journal of the National Cancer Institute.

[82]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[83]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.